Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otena

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Oct 23, 2021 4:30pm

295 Views

Post# 34041165

RE:RE:Otena

fox7mf wrote: Just opinions. The pivot from chronic to acute represents a smaller market for Otena. Dan says the market they are now pursuing represents $13b annually & they're confident, if successful, Otena could capture 20% of said market. So, I believe Otena would go for closer to $2.5b.

Fox7 ... seems the $13B is absent the label expansion strategy for migraine, dental and menstral pain.

Migraine alone could be a $2B industry.
Therefore, numbers could be different from the $13B ... but weren't provided.
Tough to say.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale